Back to search

Article

AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?

2025-08-13

Abstract excerpt

<title>Abstract</title> <p>Background Up to 60% of breast cancer patients achieve pathological complete response (pCR) and factors associated with breast-pCR have been extensively investigated. In patients with initially node-positive disease predicting axillary response to treatment remains challenging. Our study examines a biomarker panel assessed on core-biopsy lymph node metastatic tissue with the goal to est...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5b1dcd53-700b-5644-8c32-fc5e7cfe7449
DOI
10.21203/rs.3.rs-7119537/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?DOI 10.21203/rs.3.rs-7119537/v1
Epigenetic markers of tumor progression in estrogen receptor–positive breast cancer patients with high nodal involvementSemantic proximity
[Evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: correlation with molecular phenotype].Semantic proximity
Gene expression profiles associated with molecular subtypes and pathological response to neoadjuvant treatment in surgical breast cancer.Semantic proximity
A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER-2 positive breast cancerSemantic proximity
Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour responseSemantic proximity
Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database AnalysisSemantic proximity
Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapySemantic proximity
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)Semantic proximity
Predictive factors for response to neoadjuvant therapy in breast cancer.Semantic proximity
Nomogram Based on Clinicopathologic and US Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients with Biopsy-Proven Node-Positive Breast CancerSemantic proximity
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.Semantic proximity
RDH10 and ATRA sensitize triple-negative breast cancer to taxane-based chemotherapy through regulation of PIN1Semantic proximity
Select a neighboring publication to make it the new centre.